Géralyn is a senior clinical development leader with more than 35 years of international experience in Phase 1–3 drug development. She has contributed to more than 20 successful IND and NDA submissions in oncology/hematology, neurology and infectious disease. At Ensem, she serves as Clinical Lead, bringing deep expertise in clinical science and medical monitoring to the company’s clinical programs. Since 2021, she has been an independent consultant in clinical research and development. Her consulting work covers mRNA platforms, vaccines and anti-infectives, bispecific antibodies for oncology, and ASCO’s initiative to standardize oncology trial endpoints.
Before consulting, Géralyn spent most of her career in global oncology/hematology R&D. At Johnson & Johnson (Janssen) she served in a leadership position to oversee the scientific integrity of a portfolio that included four Phase 3 prostate cancer trials and hematology combination studies contributed to the approval of indications for apalutamide (Erleada®). Earlier at Janssen, she oversaw more than 100 investigator-initiated studies for VELCADE®. As a Director at Bristol-Myers Squibb, she provided medical and scientific oversight of Phase 1–4 trials in the immuno-oncology portfolio. She started her career at Berlex Canada, where she helped develop Betaseron®, the first treatment for multiple sclerosis.
Géralyn received her Ph.D. from McGill University’s Department of Neurology and Neurosurgery and did a postdoctoral fellowship in neuro-immunology at McGill, funded by the MS Society of Canada.
